Vaccinex To Report Topline Data For SIGNAL-AD Phase 1b/2 Trial Of Pepinemab In Alzheimer's Disease At The Alzheimer's Association International Conference, Philadelphia, July 31, 2024

7/17/24 8:11:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VCNX alert in real time by email

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session.

Get the next $VCNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VCNX

Date	Price Target	Rating	Analyst

More analyst ratings

$VCNX
Market Insights

Live Market Insights

Vaccinex To Report Topline Data For SIGNAL-AD Phase 1b/2 Trial Of Pepinemab In Alzheimer's Disease At The Alzheimer's Association International Conference, Philadelphia, July 31, 2024
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session.
7/17/24 8:11:21 AM ET
$VCNX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaccinex Completes Last Patient Visit In Randomized, SIGNAL-AD Phase 1b/2 Study Of Pepinemab Treatment For Alzheimer's Disease
6/6/24 8:32:40 AM ET
$VCNX
Biotechnology: Pharmaceutical Preparations
Health Care
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
5/31/24 1:17:02 PM ET
$ACIU
$ADAP
$AIRJ
$AMBA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease. Treatment with pepinemab believed to slow cognitive decline due to Alzheimer's disease: Vaccinex reported final data from its SIGNAL-AD clinical trial at the Alzheimer's Association In
11/18/24 8:30:00 AM ET
$VCNX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing Vaccinex's ActivMAb® technology to generate antibodies to complex antigen targets. In addition, Vaccinex has signed agreements to provide Charles River Labs, OmniAb, Adimab and other undisclosed strategic partners with materials to facilitate their antibody discovery programs using transg
11/7/24 8:30:00 AM ET
$VCNX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immunotherapy of Cancer's Annual Meeting (SITC) on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study (NCT04815720) for treatment of recurrent and metastatic disease
11/5/24 8:30:00 AM ET
$VCNX
Biotechnology: Pharmaceutical Preparations
Health Care

Vaccinex To Report Topline Data For SIGNAL-AD Phase 1b/2 Trial Of Pepinemab In Alzheimer's Disease At The Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Chat with this insight

Recent Analyst Ratings for
$VCNX

$VCNX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

SEC Form SC 13G filed by Vaccinex Inc.

Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

$VCNX
Market Insights

Live Market Insights